ARTICLES BY LOUIS

• The Doctor Is In At Aptuit, But Needs To Hang A New Shingle

  1/12/2015

  Surveying the biopharma service provider landscape at the New Year, a piece turned up missing … A frank discussion with CEO Jonathan Goldman.

• A Happy 2015 For Biopharma Industry? Put It In The Contract

  1/6/2015

   

  Is it too early to move from confetti to contracts? Perhaps, so let’s ease into one of 2015’s most important topics: the contracting ecosystem that now makes up the global biopharmaceutical industry.

   

• Employment A Leading Indicator For Pharma Industry

  12/22/2014

  2014 saw the continuation of many trends. But the one variable that most affects individuals and demonstrates industry strength or weakness is the ebb-and-flow of employment.

• Biopharma Outsourcing Shall Be Revealed

  12/16/2014

  Pharmaceutical and biotechnology (biopharma) outsourcing is an unknown quantity to the global healthcare consumer. This will change and the biopharma industry ought to get in front of it.

• Place Matters In A Global Pharmaceutical Industry

  12/5/2014

  Organizations gain competitive advantage if they integrate aspects of  “place” by moving from the local geographic to a global overview, and from the functional to the psychological aspects associated with both realms.    

• Diesels To Drugs: What Trucks Teach Pharma About Quality And Leadership

  12/1/2014

  Mikael Ericson worked for Scania, the renowned global leader in the manufacture of heavy trucks and buses. That, for him, logically led to a 12-year career at AstraZeneca. Which, with a more intuitive logic, led to his September appointment as CEO at Kemwell AB, the Swedish arm of the India-based contract development and manufacturing organization.

• At Global Forum, Pharma Outsourcing Stakeholders Reveal Some Truths

  11/21/2014

  The stage was the Outsourced Pharma West conference in the Hyatt Regency in San Francisco. Some of the discussion swirled around big pharma’s full-scale incursion into China, perhaps for some unexpected reasons, and the contemplation of wringing “some risk” out of an India dependency. 

• Outsourced Pharma West Participants Question One-Stop-Shop Model

  11/17/2014

  The industry trend of the “One-Stop-Shop” biopharmaceutical service provider took a rhetorical hit at the inaugural Outsourced Pharma West conference.  Executives from Merck, Pfizer and AZ mentioned they didn’t believe the concept could work and were not sure why it was so much in vogue. 

• Dow Assists Drug Delivery With Excipients And Outsourcing

  11/14/2014

  Dow Pharma & Food Solutions (DP&FS) has focused intently on improving a specific area of the pharmaceutical industry: solubility, and thus bioavailability, in new and existing drugs. In Dow’s advancement and supplying of polymers as excipients, it works hand-in-hand with outsourcing service providers. But don’t call Dow itself a provider.

• WuXi Historic Company In Pharma Outsourcing

  11/3/2014

  Hard to argue with the categorical proposition that no single entity has fundamentally influenced the growth and shape of global pharma outsourcing as has WuXi of Shanghai. What has been debated is the nature of that impact on the industry. I sat down with Todd D. Nelson, Ph.D., VP of Operations, Alliance Management and Business Development, WuXi STA, to discuss.